Owner Scorecard


← All companies ← SNDR Manual SNEX → ← SNDL Pharmaceuticals SNY →

SNDX, Syndax Pharmaceuticals Inc.

Pharmaceuticals consumer brand UnprofitableDistress / turnaround

We are a commercial-stage biopharmaceutical company advancing innovative cancer therapies.

We currently have two commercially approved medicines, Revuforj (revumenib) and Niktimvo (axatilimab-csfr), and a robust slate of clinical development programs designed to unlock the full potential of our first two products.

Niktimvo is our first-in-class colony stimulating factor-1 receptor, or CSF-1R, blocking antibody that was approved by the FDA in August 2024 for the treatment of chronic graft-versus-host disease, or cGVHD, after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg.

Latest annual: FY2025 10-K
SNDX · Syndax Pharmaceuticals Inc.
I

The business

What it sells, where the money comes from, the kind of company it is.

Revenue · FY2025
$172M
+627.8% YoY · 158% 5-yr CAGR
Vital signs · TTM, with 5-yr average
Revenue $252M 5-yr avg $67M
Operating margin −77.0% 5-yr avg −69.8%
ROIC −536% 5-yr avg −44%
Owner-earnings margin −88% 5-yr avg −83%
Free cash flow margin −88% 5-yr avg −443%

Next report Est. 10/27–11/5 · the 10-Q for the quarter ended late September · due within 40 days of period end · has filed ~35 days after · the wire records it on arrival

The business in brief

read the 10-K →

What this business is and what moves its needle, from its own SEC filings.

What it is
Revenue is Net product revenue (72%), Collaboration revenue (25%) and Milestone Revenue (3%).
Situation
Unprofitable. No sustained operating profit across the record; an earnings multiple has nothing to rest on. What the record does show is revenue, the gross-margin trajectory, and the burn against the cash on hand. Distress / turnaround. Thin interest coverage, or operating cash burned against real debt, across the record. The balance sheet carries this situation; the debt schedule sets the clock.
What moves the needle
The pipeline against the patent cliff, and pricing. What decides it: whether new drugs replace those losing exclusivity, the odds in the clinical pipeline, and how durable pricing stays against payers and generics. On its own account, the filing leans hardest on pricing power & competition, set against the numbers in what the filing emphasizes, below.
Is it a good business?
Return on capital has rarely cleared the cost of capital (median −64%, above 15% in 0 of 10 years). Owner earnings, the cash-based check, have been thin too. This is price-taker territory, where the balance sheet and the cycle matter more than any multiple; the rest is in the 10-K.

Every line is arithmetic on the company's filings, shown in full in the sections below.

Where the money comes from

read the 10-K →

Net product revenue is 72% of revenue, with Collaboration revenue the other meaningful line at 25%.

Revenue by product line, FY2025
  • Net product revenue72%$125M
  • Collaboration revenue25%$42M
  • Milestone Revenue3%$5M

From the segment footnote of the company's own 10-K. Shares are of total revenue; the profit bar shows each segment's share of segment operating profit, before unallocated corporate costs.

II

The record

Ten years of arithmetic, read across the cycle.

The record, 2016–2025

realized figures from each filing · older years to the left
2016’162017’172018’182019’192020’202021’212022’222023’232024’242025’25TTMTTMJun 2026
Income statement
$1M$2M$2M$2M$2M$140M$0$0$24M$172M$252MRevenueRevenue
n/m752%n/mn/mn/m18%510%104%71%SG&A / revenueSG&A/rev
n/mn/mn/mn/mn/m63%n/m150%104%R&D / revenueR&D/rev
($44M)($62M)($76M)($58M)($71M)$26M($152M)($230M)($340M)($273M)($194M)Operating incomeOp. inc.
n/mn/mn/mn/mn/m18.8%n/m−158.4%−77.0%Operating marginOp. mgn
($44M)($61M)($74M)($56M)($73M)$25M($149M)($209M)($319M)($285M)($221M)Net incomeNet inc.
Cash flow & returns
($35M)($47M)($69M)($51M)($71M)$29M($134M)($161M)($275M)($323M)($221M)Operating cash flowOp. cash
$89K$76K$78K$92K$90K$43M$33M$12M$8M$6M$15MDepreciationDeprec.
$5M$8M($849K)($662K)($7M)($52M)($33M)$6M($7M)($91M)($64M)Working capital & otherWC & other
$261K$84K$187K$0$129K$0$0$0$187K$187KCapexCapex
21.4%4.0%12.3%0.0%0.1%0.0%0.1%0.1%Capex / revenueCapex/rev
($35M)($47M)($69M)($71M)$29M($134M)($161M)($275M)($323M)($221M)Owner earningsOwner earn.
n/mn/mn/mn/m20.8%n/m−187.5%−87.5%Owner earnings marginOE mgn
($35M)($47M)($69M)($71M)$29M($134M)($161M)($275M)($323M)($221M)Free cash flowFCF
n/mn/mn/mn/m20.8%n/m−187.5%−87.5%Free cash flow marginFCF mgn
($18M)($17M)$51M$13M($143M)($41M)($186M)$118M($220M)$290MInvesting cash flowInv. cash
$54M$76M$16M$29M$304M$118M$172M$264M$353M$14MFinancing cash flowFin. cash
$762K$11M($1M)($9M)$91M$107M($148M)$221M($141M)($19M)Change in cashΔ cash
-57%-71%-311%-650%-41%14%-30%-70%-57%-77%-536%ROICROIC
-53%-58%-139%-177%-29%6%-32%-38%-111%-442%-1462%Return on equityROE
−53%−58%−139%−177%−29%6%−32%−38%−111%−442%n/mRetained to equityRetained/eq
Balance sheet
$105M$130M$81M$60M$293M$440M$476M$571M$573M$394M$548MCash & investmentsCash+inv
$0$8M$38M$38MReceivablesReceiv.
$0$366K$33M$33MInventoryInvent.
$2M$2M$1M$6M$4M$6M$4M$10M$12M$17M$5MAccounts payablePayables
($10M)($4M)$54M$66MOperating working capitalOper. WC
$109M$133M$83M$62M$299M$448M$490M$581M$603M$528M$675MCurrent assetsCur. assets
$10M$16M$16M$18M$19M$21M$29M$58M$104M$120M$100MCurrent liabilitiesCur. liab.
10.5×8.4×5.2×3.4×15.8×21.7×16.9×10.0×5.8×4.4×6.8×Current ratioCurr. ratio
$260K$267K$373K$281K$192K$278K$20K$8K$0$181KNet PP&ENet PP&E
$109M$137M$84M$64M$301M$450M$497M$613M$725M$530M$704MTotal assetsAssets
$0$338M$350M$350MTotal debtDebt
($571M)($235M)($44M)($198M)Net debt / (cash)Net debt
-30.3×13.8×-48.4×-1105.5×-45514.0×-97085.5×Interest coverageInt. cov.
$25M$33M$31M$32M$48M$41M$30M$59M$437M$465MTotal liabilitiesTotal liab.
$84M$104M$53M$32M$252M$408M$467M$554M$288M$65M$15MShareholders’ equityEquity
385.9%258.5%408.8%395.8%597.0%9.5%181.7%27.6%19.6%Stock comp / revenueSBC/rev
Per share
14.6M21.0M25.4M30.5M41.3M53.6M60.8M70.4M85.6M86.6M88.6MShares out (diluted)Shares
$0.08$0.10$0.06$0.05$0.04$2.61$0.00$0.00$0.28$1.99$2.85Revenue / shareRev/sh
$-3.04$-2.90$-2.92$-1.84$-1.77$0.46$-2.46$-2.98$-3.72$-3.29$-2.49EPS (diluted)EPS
$-2.41$-2.26$-2.70$-1.73$0.54$-2.20$-2.28$-3.21$-3.73$-2.49Owner earnings / shareOE/sh
$-2.42$-2.26$-2.71$-1.73$0.54$-2.20$-2.28$-3.21$-3.73$-2.49Free cash flow / shareFCF/sh
$0.02$0.00$0.01$0.00$0.00$0.00$0.00$0.00$0.00$0.00Cap. spending / shareCapex/sh
$5.76$4.97$2.09$1.04$6.11$7.62$7.69$7.88$3.37$0.75$0.17Book value / shareBVPS

The diluted share count moved ×1.44 into 2017 — shares issued, not a split the totals corroborate — and the per-share figures carry the counts as filed.

Per-share growththe realized rate an owner's share compounded
9-yr5-yr
Revenue / share+42.2%/yr+122.2%/yr
Capital spending / share−20.9%/yr
Book value / share−20.3%/yr−34.3%/yr

Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.

In fiscal 2025 the business reported a $285M loss but ($323M) of owner earnings: $38M less than the profit line, taken out by capital spending and the timing of cash.

FY2025FY2024FY2023FY2022FY2021
Reported net income($285M)($319M)($209M)($149M)$25M
Depreciationnon-cash charge added back+$6M+$8M+$12M+$33M+$43M
Stock-based compensationreal costnon-cash, but a real cost+$48M+$43M+$31M+$16M+$13M
Working capital & othertiming of cash in and out, other non-cash items−$91M−$7M+$6M−$33M−$52M
Cash from operations($323M)($275M)($161M)($134M)$29M
Capital expenditurecash put back in to keep running and to grow−$187K−$129K
Owner earnings($323M)($275M)($161M)($134M)$29M
Owner-earnings marginowner earnings ÷ revenue-188%-1161%21%

Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position . The cash-flow statement also adds stock comp back as non-cash, but it is a real cost paid in shares; counted as the expense it is (less $48M), owner earnings is nearer ($371M).

Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.

III

Quality & stewardship

Returns, the balance sheet, capital allocation, and pay.

Owner’s Scorecard

FY2025 10-K · source on SEC EDGAR →

Will it survive?

  • Does not cover its interest
    Operating income ($273M) ÷ interest expense $6K
    What this means

    A full year of operating profit didn't cover the interest bill. This is the zombie zone: the business depends on refinancing, asset sales, or forbearance to service its debt.

  • Net cash
    Cash $135M + ST investments $259M − debt $350M
    What this means

    Cash and short-term investments exceed every dollar of debt by $44M, on net the company owes nothing, and can act from strength when others can't. Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.

  • Not enough data
    What this means

    The filing data didn't include the inputs for this check.

Is it a good business?

  • Below average through the cycle
    10-yr median, range -650%–14%; -77% latest = NOPAT ($216M) ÷ invested capital $280M
    Industry peers: median -50%
    What this means

    The rate the business earns on the money tied up in it, Buffett's north star, because over time a stock tracks the ROIC beneath it. Above ~15% sustained hints at a moat; a return below the cost of capital (~8%) erodes value as a business grows rather than building it — the test Buffett weighs most. The headline is the median of the last 10 years (it ran -77% most recently), so one peak or trough year doesn't set the verdict. Asset-light businesses (R&D expensed, little capital) read artificially high, pair this with Owner Earnings.

  • Consumes cash
    Owner earnings ($323M) = operating cash ($323M) − maintenance capex $187K
    Industry peers: median -95%
    What this means

    What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's -188% of revenue this year. Treating stock comp as the real expense it is (less $48M of SBC) leaves ($371M).

  • Loss, and burning cash
    Net income ($285M) · cash from operations ($323M)
    What this means

    The company reported a net loss, so a conversion ratio isn't meaningful. What matters then is whether operations still threw off cash, here, they did not.

How is the cash used?

  • Not enough data
    What this means

    The filing data didn't include the inputs for this check.

  • Investing or harvesting? 0.03×
    Harvesting
    Capex $187K ÷ property depreciation $6M
    What this means

    Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.

The promise and the pay packet

  • Is the buyback buying ownership, or mopping up? 27.6%
    The count is rising
    Stock compensation $48M (fiscal 2025), 27.6% of revenue · no repurchases · diluted shares +42.6% since 2022
    What this means

    Stock handed to employees is a real cost paid in the owner's own currency: it is charged against profit, but the shares it creates are permanent. Many companies repurchase stock at the same time, which looks like a return of capital and often is not — if the count barely moves, the cash merely cancelled the pay packet and bought the owner nothing. The three states worth telling apart are a count genuinely shrinking, a count standing still despite large repurchases, and a count rising because the issuance was never offset at all.

Graham’s defensive tests · 2 of 4 met

Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.

  • Adequate size Miss
    Revenue ≥ $2B · $172M
    What this means

    Big enough to weather a storm. Graham's 1972 floor was ~$100M of sales (≈ $700M today); we use a $2B revenue line as a conservative modern stand-in.

  • Strong liquidity Pass
    Current ratio ≥ 2× · 4.40×
    What this means

    Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.

  • Conservative debt Pass
    Debt ≤ working capital · $350M vs $408M WC
    What this means

    Graham's rule that borrowings not exceed net current assets. Capital-heavy and buyback-heavy firms routinely fail it, read it next to interest coverage, not alone.

  • Earnings stability Miss
    A profit every year (10-yr record) · 9 loss years
    What this means

    Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.

  • Dividend record
    Uninterrupted dividends · no dividend line tagged in the data
    What this means

    An unbroken dividend was Graham's mark of durability. This record carries no dividends-paid line in any year — common for partnerships, whose distributions file under tags the chain doesn't read — so the criterion is withheld rather than judged on silence.

  • Earnings growth
    Earnings +33% over the record ·
    What this means

    Earnings were negative early in the record, a growth rate isn't meaningful.

  • Moderate price
    P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
    What this means

    Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are $-3.04/share (latest year $-3.20), the averaged base the calculator's gate runs on, and book value is $0.72/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.

Durability & moat, 2016–2025

Whether the record’s returns held, and what the capital reinvested earned.

  • Profitable years 1 of 10
    What this means

    Lost money in 9 year(s), look at what happened there before trusting the average.

  • Return on capital ≥ 15% 0 of 3 yrs
    What this means

    A moat shows up as a high return on invested capital that holds year after year, not one good vintage.

  • Operating margin −3843% → −525% (3-yr avg ends)

    In the filing’s words The record and the words agree: the margin widened and the filing attributes the gain to its own pricing, not volume alone.

    What this means

    Through the cycle the operating margin widened — about −3843% early to −525% lately, median −3587% — pricing power intact or improving.

  • Reinvestment, incremental ROIC returns capital
    What this means

    The capital base barely grew: this business returns cash through dividends and buybacks rather than reinvesting. Judge it on the cash returned, not on compounding.

  • Worst year 2018 · −5001.7% op. margin
    What this means

    Operations went underwater in 2018, understand why before trusting the good years.

All figures as filed; the source filing is linked above.

Current Position

as of the latest quarter, Jun 30, 2026

Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.

Current assets$675M
  • Cash & short-term investments$548M
  • Receivables$38M
  • Inventory$33M
  • Other current assets$56M
Current liabilities$100M
  • Debt due within a year$350M
  • Accounts payable$5M
Current ratio6.77×all current assets ÷ what's due · Graham looked for 2×
Quick ratio6.44×stricter: inventory excluded
Cash ratio5.50×strictest: cash alone against what's due
Working capital$575Mthe cushion left after near-term bills
Debt due this year vs. cash$350M due · $548M cash covered by cash on hand, no refinancing forced · both figures from the Jun 30, 2026 balance sheet
Cash runway2.5 yrsthe business is consuming cash; this is how long the cash on hand lasts at that rate
Revenue, latest quarter vs. a year ago+91.8%the freshest read on whether the business is still growing
Current ratio, recent quarters7.0× → 6.8×
Deeper floors
Tangible book value$15Mequity stripped of goodwill & intangibles
Net current asset value($14M)Graham's net-net: current assets less all liabilities
Debt incl. operating leases$351M$506K of it operating leases

From the company's latest filing.

Management, ownership & pay

read the proxy →

From the proxy: how much of the business the people running it own, and how they are paid, beside what the business earned for its owners in the same years.

Fiscal yearChief executivePay, as filed“Actually paid”Owner earnings
2021Briggs W. Morrison$3.9M$2.9M$29M
2022Briggs W. Morrison$2.4M$3.5M($134M)
2022Michael A. Metzger$4.1M$6.3M($134M)
2023Michael A. Metzger$9.1M$5.2M($161M)
2024Michael A. Metzger$7.7M$1.6M($275M)
2025Michael A. Metzger$7.1M$11.1M($323M)

Both pay figures are the company’s own, from the pay-versus-performance table its proxy statement files. “As filed” is the Summary Compensation Table total: salary, bonus, and equity awards at their value on the day of grant. “Actually paid” is the SEC’s prescribed recalculation, which re-marks those equity awards to what they became as they vested; it can swing far above or below the filed figure in either direction, and negative years occur. Owner earnings are the whole business's, from the record above, for the same fiscal years.

  • Insider ownership4.8%

    The stake all directors and executive officers hold together, per the 2026 proxy: skin in the game, the first thing Munger reads.

  • Stock-based compensation$48M

    The slice of the business handed to employees in shares in fiscal 2025, 27.6% of revenue. Buffett's oldest accounting fight: this is compensation, compensation is an expense, real whether or not the headline earnings admit it. One trap: the cash-flow statement adds SBC back, so the operating cash, and the owner earnings drawn from it, are flattered by exactly this amount; counted as the cost it is, what an owner keeps is lower.

What an owner would ask, FY2025

read the 10-K →
  • Which reported numbers are a judgment call?
    Management names Revenue recognition, Stock compensation as critical estimates

    each rests partly on management's judgment; the filing's note sets out the assumptionsverify →

The questions the record and the charts do not answer on their own; each carries the figure and the place to look.

Peers, Pharmaceuticals

The same industry, side by side on owner economics. Each column names the period it is read over, and a median resting on fewer than three years carries that count beside it; the group median at the foot is the line to read each figure against.

CompanyRevenuelatest FY, USDGross marginmedian over the recordOp. marginmedian over the recordROICmedian over the recordOwner earn. marginmedian over the record
RYTMRhythm Pharmaceuticals Inc.$190M90%-221.1%4y-67%-132%4y
MRVIMaravai LifeSciences Holdings Inc.$186M53%16.8%-32%21%
STOKStoke Therapeutics Inc.$184M-277.3%-79%-238%
KMDAKamada Ltd.$180M36%9.8%11%9%
CYRXCryoPort Inc.$176M46%-44.0%-14%-17%
PHATPhathom Pharmaceuticals Inc.$175M86%-296.8%2y-289%2y
SNDXSyndax Pharmaceuticals Inc.$172M-69.8%2y-64%-83%2y
LQDALiquidia Corporation$158M76%-341.3%-163%-255%
Group median-145.5%-64%-108%
IV

The price

What a price has to assume.

What the price implies

reverse-DCF

Syndax Pharmaceuticals Inc. is profitable, but owner earnings are negative this year because capital spending currently outruns operating cash, a build-out, so the owner-earnings reverse-DCF has no positive base to grow. We read the price from both ends instead: type a price to see the steady-state profitability it demands, then set the mature margin you would believe and weigh the two against each other. Nothing leaves your browser unless you enter it in your notebook.

$
The assumptions

Enter a price to run it.

Owner earnings it must reach
Margin the price demands
Owner-earnings margin today−88%

Two reads of one future. From your price: the owner earnings the company must reach, valued at a mature multiple and discounted back at your rate, expressed as the margin it implies on revenue grown at your rate. From your belief: the mature margin you would credit, set on the dial above. When the margin the price demands runs above the one you would believe, you are paying for a future taken on faith. For a deep cyclical at a trough, normalized through-cycle earnings are the better lens; this mode is for the genuinely unprofitable, and for the profitable business whose capital spending currently outruns its cash.

Cite: Owner Scorecard, "Syndax Pharmaceuticals Inc. (SNDX), the owner's record," https://ownerscorecard.com/c/SNDX, data as of 2026-08-17.

Manual order: ← SNDR its page in the Manual SNEX →

Industry order: ← SNDL the Pharmaceuticals chapter SNY →